ArticleHypertension (Dallas, Tex. : 1979)2007
Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats.
Article in Hypertension (Dallas, Tex. : 1979), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 54 citations in OpenAlex.
- Microvascular angiotensin II type 2 receptor function is enhanced in young females and declines in a model of murine aging.The journal of cardiovascular aging · 2024Article
- Functional, Structural and Proteomic Effects of Ageing in Resistance Arteries.International journal of molecular sciences · 2024Review
- The Angiotensin ATPharmacological reviews · 2022Review
- Control of aging by the renin-angiotensin system: a review ofFrontiers in pharmacology · 2022Review
- Attenuation of Angiotensin II-Induced Hypertension in BubR1 Low-Expression Mice Via Repression of Angiotensin II Receptor 1 Overexpression.Journal of the American Heart Association · 2019Article
- Mycophenolate Mofetil Attenuates DOCA-Salt Hypertension: Effects on Vascular Tone.Frontiers in physiology · 2018Article
- Microvascular vasodilator properties of the angiotensin II type 2 receptor in a mouse model of type 1 diabetes.Scientific reports · 2017Article
- International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Pharmacological reviews · 2015Review
- AT2 receptor activities and pathophysiological implications.Journal of cardiovascular pharmacology · 2015Review
- The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.Journal of molecular medicine (Berlin, Germany) · 2014Review
- COX-2-derived prostanoids and oxidative stress additionally reduce endothelium-mediated relaxation in old type 2 diabetic rats.PloS one · 2013Article
- Effects of aging, TNF-α, and exercise training on angiotensin II-induced vasoconstriction of rat skeletal muscle arterioles.Journal of applied physiology (Bethesda, Md. : 1985) · 2012Article
- Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats.International journal of hypertension · 2012Article
- Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.Diabetologia · 2010Article
- AT2 receptors: functional relevance in cardiovascular disease.Pharmacology & therapeutics · 2008Review
- Chemistry and antihypertensive effects of tempol and other nitroxides.Pharmacological reviews · 2008Review
- Physical (in)activity and endothelium-derived constricting factors: overlooked adaptations.The Journal of physiology · 2008Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of angiotensin II type 2 receptors (AT2Rs) remains a matter of controversy. Its vasodilatory and antitrophic properties are well accepted. Nevertheless, in hypertensive rats, AT2R stimulation induces a vasoconstriction counteracting flow-mediated dilation (FMD). This contraction is reversed by hydralazine. Because FMD is also decreased in aging, another risk factor for cardiovascular diseases, we hypothesized that AT2R function might be altered in old-rat resistance arteries. Mesenteric resistance arteries (250 mum in diameter) were isolated from old (24 months) and control (4 months) rats receiving hydralazine (16 mg/kg per day; 2 weeks) or water. FMD, NO-mediated dilation, and endothelial NO synthase expression were lower in old versus control rats. AT2R blockade improved FMD in old rats, suggesting that AT2R stimulation produced vasoconstriction. AT2R expression was higher in old rats and mainly located in the smooth muscle layer. In old rats, AT2R stimulation induced endothelium-independent contraction, which was suppressed by the antioxidant Tempol. Reactive oxygen species level was higher in old-rat arteries than in controls. Hydralazine improved FMD and NO-dependent dilation in old rats without change in AT2R expression and location. In old rats treated with hydralazine, reactive oxygen species level was reduced in endothelial and smooth muscle cells, and AT2R-dependent contraction was abolished. Thus, AT2R stimulation induced vasoconstriction through activation of reactive oxygen species production, contributing to decrease FMD in old-rat resistance arteries. Hydralazine suppressed AT2R-dependent reactive oxygen species production and AT2R-dependent contraction, improving FMD. Importantly, endothelial alterations in aging were reversible. These findings are important to consider in the choice of vasoactive drugs in aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.